Added to YB: 2026-10-08
Pitch date: 2026-10-04
KYTX [bullish]
Kyverna Therapeutics, Inc.
-5.24%
current return
Author Info
No bio for this author
Company Info
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases.
Market Cap
$390.9M
Pitch Price
$6.30
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.47
P/E
-2.19
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Free under $10 Ticker Biotech Quarter Review Tier 1 basket — strategic biotech and specialty pharma - Kyverna Therapeutics, Inc.
KYTX (quick overview): Kyverna’s KYV-101 is a CD19 CAR-T program spanning myasthenia gravis, stiff-person syndrome and lupus nephritis. At a $6.31 share price, the strategic case does not require success in every indication: one clean registrational path in a high-value disease could be enough for a chronic-immunology company to pursue a partnership or acquisition. Key risks are durability, safety, manufacturing, treatment infrastructure, reimbursement and proving sufficient benefit versus established chronic therapies.
Read full article (1 min)